Loading organizations...

The better way to run single cell genomics
Key people at Dropprint Genomics.
Dropprint Genomics was founded in 2019 by Jimmie Ye (Founder) and Rachel Gate (Founder) and Meena Subramaniam (Founder).
Who we are?
We write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at the speed of each individual car. This is the beauty of single cell genomics, we can now identify that speeding car.
Why now?
The biggest barrier for entry into the single cell genomics market are cost and data analysis. To that end, we have reduced the cost by 10-fold and built the computational infrastructure for scalability. Although single cell sequencing has only been around for about five years, we come from one of the top single cell genomics labs and were the first to process and analyze millions of immune cells. Thanks to our software solutions, we have been able to bring big data solutions to the immune system.
Where are we and where are we going?
We have generated a database of over 1 million immune cells spanning healthy, cancerous, and autoimmune immune cells and are growing through paid partnerships. Harnessing out database and ML software, we can take a data-centric approach for better target discovery. Fortunately, as our database continues to grow, our models will continue to learn for more precise, unbiased, and automated single cell genomics.
Thank you!
Dropprint Genomics was founded in 2019 by Jimmie Ye (Founder) and Rachel Gate (Founder) and Meena Subramaniam (Founder).
Dropprint Genomics is a Y Combinator-backed startup that developed advanced computational infrastructure to enable scalable single-cell genomics analysis, focusing on understanding the activity of individual cells rather than bulk averages. Their software significantly reduces the cost of single-cell sequencing by about tenfold and supports large-scale data processing, which is crucial for precise immune system insights. The company built a database of over one million immune cells spanning healthy, cancerous, and autoimmune conditions, serving researchers and biopharma partners aiming to improve target discovery and therapeutic development through data-centric approaches[3][5].
In 2021, Dropprint Genomics was acquired by Immunai, a biotech company specializing in single-cell functional genomics combined with AI to advance immune-powered medicines. This acquisition expanded Immunai’s immune cell database and strengthened its platform, AMICA, which is the world’s largest single-cell immune knowledge base. Immunai leverages Dropprint’s technology to accelerate discovery, prioritization, and development of new therapies, particularly in cancer and autoimmune diseases[1][2][4].
Dropprint Genomics was founded by Rachel Gate, Meena Subramaniam, and Jimmie Ye, emerging from top single-cell genomics labs with deep expertise in immune cell analysis. The idea originated from the need to overcome the high cost and computational challenges of single-cell sequencing, enabling scalable and precise analysis of individual cells rather than bulk populations. Early traction included processing and analyzing millions of immune cells and establishing paid partnerships to grow their immune cell database[3].
The company was acquired by Immunai in March 2021, which itself was founded in 2018 with a mission to revolutionize drug discovery through single-cell multiomics and AI. Immunai’s acquisition of Dropprint was a pivotal moment that enriched its AMICA platform and expanded its capabilities in immune cell data integration and analysis[1][2][4].
Dropprint Genomics rides the wave of single-cell genomics and AI-driven precision medicine, a rapidly growing trend in biotechnology. The timing is critical as single-cell sequencing technologies have matured over the past five years, but cost and data analysis remain barriers. Dropprint’s innovations address these challenges, enabling scalable, cost-effective analysis that fuels deeper understanding of immune mechanisms in health and disease.
Market forces favor solutions that integrate large-scale biological data with AI to accelerate drug discovery and personalized medicine. By enabling detailed immune cell profiling, Dropprint contributes to the broader ecosystem of functional genomics, immunotherapy, and computational biology, influencing how biopharma companies develop next-generation therapies[1][3][4].
Following its acquisition by Immunai, Dropprint Genomics is positioned to play a key role in advancing precision immunotherapy through enhanced single-cell data infrastructure and AI integration. The ongoing expansion of the AMICA platform toward a billion-cell atlas will further empower discovery and clinical translation.
Future trends shaping Dropprint’s journey include increasing adoption of multiomic single-cell technologies, growing demand for AI-powered biological insights, and the push toward personalized medicine in oncology and autoimmune diseases. As the immune cell database and machine learning models grow, Dropprint’s influence will likely deepen, enabling more precise, automated, and scalable single-cell genomics analysis that drives new therapeutic breakthroughs[1][4].
This evolution ties back to Dropprint’s original mission of making single-cell genomics accessible and scalable, transforming how researchers and clinicians understand cellular activity at unprecedented resolution.
Key people at Dropprint Genomics.